Compare United Microelectronics Corp (UMC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? United Microelectronics Corp trades at $19.39 (market cap $47.80B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× United Microelectronics Corp's market cap, and United Microelectronics Corp pays a 2.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| UMC | VRTX | |
|---|---|---|
Market Cap | $47.80B | $132.79B |
Sector | Technology | Health |
52-Week High | $28.02 | $529.65 |
52-Week Low | $6.58 | $376.62 |
Enterprise Value | $44.92B | $126.92B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $18.72, down 2.5% today, amid a bearish technical signal with key resistance at $19. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.54 vs. $0.16 expected, and announced fab expansions in Singapore and Taiwan to meet AI-driven demand. Revenue growth is projected to rise to $250.7B in 2026, with a net income margin of 32.75%, though profit margins have declined from 2022 peaks. Analyst sentiment is mixed, with 26.7% buy ratings but a majority hold consensus.
The outlook for UMC is cautiously optimistic, driven by AI expansion and solid profitability, but risks include competitive pressures and margin compression. Near-term price action hinges on breaking resistance at $19, with support at $18. Institutional activity shows mixed positioning, reflecting uncertainty over execution amid capital expenditure increases.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
